PHILADELPHIA, PA and CAMBRIDGE, MA – Two grants for research that could transform cancer therapies have been funded through an innovative partnership between the American Association for Cancer Research (AACR) and MPM Capital through its management of the UBS Oncology Impact Fund (OIF). This unique grant program allows investigators who can make a significant impact […]
The AACR-MPM Oncology Charitable Foundation Announces First Grants to Support Transformative Cancer Research
12:05 pm By
Ropeginterferon Effective Treatment for Polycythemia Vera
5:41 pm By
Thrombotic Risk Reduction and High Rate of Complete Molecular Response with the Long Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study, ASH 2019 interview with Dr. Kiladjian by David Wallace Dr. Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at […]
PV Reporter Attends MPN Horizons 2019, 4th Annual Global Conference
5:09 pm By
4th year in Attendance by David Wallace On October 25th, 2019 approximately 50 MPN advocates representing over 25 advocacy groups from around the world met in Lisbon, Portugal for 3 days. The objective was to share best practices of support and advocacy activities, learn about new MPN research and discuss issues that patients in each […]
MPN Caregiver Spotlight
6:13 pm By
November is National Family Caregivers Month – What does it mean to be a caregiver? by Ina Gunson I am a 35 year old taking care of my 65 year old mother, Ruth who will be turning 66 next month. We have a very close bond, my Mom is my best friend. In 2017, she […]
Zantac Recall Expands, New Options help PV patients calm Itching
7:16 pm By
MPN Patients have multiple Over The Counter options to relieve Itching! by Jennifer Acker For many PV patients the combination of Zantac (an H2 blocker) and Zyrtec (an H1 blocker) have been effective in providing relief from pruritus, a severe itching condition that is a common MPN symptom. PV Reporter first uncovered this impressive treatment […]
Podcast
5:22 am By
MPN Chronicles Podcasts This Podcast will cover many elements of my Polycythemia Vera (PV) journey, from the day of diagnosis til present. Hopefully you will find tips in living with an MPN that you can relate to, while understanding the need to become your own advocate. The Podcast is not to be construed as medical […]
Geron Granted Fast Track Designation on Imetelstat for MF
6:29 pm By
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) — Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2 or High-risk myelofibrosis (MF) whose […]
05: Tips to Living Well with an MPN
11:11 am By
MPN Chronicles Podcast – 05, Tips to healthy living with a Myeloproliferative Neoplasm by David Wallace It’s important for us, as patients to do everything we can naturally to help our body fight MPNs. Here are a few tips: • Eating right, a balanced diet is especially important if you have an MPN as eating […]
MPNs and Insomnia: Tips for Better Sleep
5:08 pm By
65% of Myeloproliferative Neoplasm, Cancer Patients report Sleep Problems Part 5 in a New Series – “Addressing MPN Symptoms” (2019) by Heidi Cascarano Many people struggle with sleep disturbances, and we all know that lack of quality sleep can lead to daytime fatigue, diminished quality of life, and other health problems. What’s worse is that […]
Inrebic (Fedratinib) receives FDA Approval for Myelofibrosis
3:01 pm By
The First New Treatment in Nearly a Decade for MF Patients INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or […]
